iBio, Inc. (IBIO) Stock: Why It’s Headed For The Bottom


iBio, Inc. (IBIO) is making a move down in the market today. The stock, focused on the biotech space, is presently trading at $0.17 after tumbling -10.47% so far today. As it relates to biotech companies, there are a number of aspects that have the ability to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines associated with IBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-25-19 08:30AM iBio, Inc. Prices $5,000,000 Public Offering
Oct-22-19 04:30PM iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
Sep-19-19 01:58PM One Thing To Remember About The iBio, Inc. (NYSEMKT:IBIO) Share Price
Sep-17-19 04:15PM iBios Collaboration with South Africas AzarGen Biotechnologies Advances to Next Stage
Aug-26-19 05:30PM iBio and CC-Pharming Expand Business Collaboration in China

However, any time investors are making a decision with regard to investing, investors should look at much more than just news, this is especially the case in the generally speculative biotechnology sector. Here’s what’s happing when it comes to iBio, Inc..

Recent Movement From IBIO

Although a decline in a single session, like the move that we’re seeing from iBio, Inc. may make some investors upset, a single session move by itself should not be the basis of a decision to, or not to, invest in a stock. It’s generally smart to dig into trends experienced by the stock for a period longer than a single trading day. As it relates to IBIO, below are the returns on investment that investors have experienced:

  • Past 7 Days – Throughout the past 7 days, IBIO has seen a change in value amounting to -70.44%.
  • Monthly – The return on investment from iBio, Inc. over the last 30 days works out to -68.50%.
  • Past 3 Months – Throughout the past three months, the company has generated a return of -74.63%
  • Past 6 Months – Throughout the last six months, we’ve seen a performance that equates to -79.99% from the company.
  • Year To Date – Since the the last trading session of last year IBIO has generated a return on investment of -77.42%.
  • Full Year – Finally, in the last year, we’ve seen movement in the amount of -78.40% from IBIO. In this period of time, the stock has sold at a high of -87.85% and a low price of -6.54%.

Key Ratios

Looking at a few key ratios having to do with a stock generally gives traders a look of how dangerous and/or potentially profitable a pick may be. Below are a few of the key ratios to look at when digging into IBIO.

Short Ratio – The short ratio is a tool that’s used by investors to measure the amount of short interest. The higher this ratio, the more investors are expecting that the price of the stock is headed for declines. In general, biotech stocks tend to carry a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, in relation to iBio, Inc., it’s short ratio clocks in at 0.91.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure the company’s abilities to cover its debts as they mature with only quick assets or current assets. In the biotechnology sector, companies are heavily reliant on the continuation of investor support, the current and quick ratios can be upsetting. Nonetheless, some gems in the biotechnology industry come with positive quick and current ratios. In terms of IBIO, the quick and current ratios come to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price. In this particular case, the book to share value ratio equates to 0.12.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is an important ratio to think about. In this case, the cash to share value works out to 0.18.

What Analysts Say About iBio, Inc.

Although it’s never a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to use their analysis when validating your own before making investment decisions in the biotech sector. Here are the most recent moves that we’ve seen from analysts when it comes to IBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With iBio, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in IBIO, here’s what we’re seeing:

Institutions own 26.90% of the company. Institutional interest has moved by 297.93% over the past three months. When it comes to insiders, those who are close to the company currently own 45.24% percent of IBIO shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 24.29M shares of iBio, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IBIO has a float of 15.54M.

It’s also important to dig into the short percent. Think about it, when a high portion of the float available for trading is sold short, the overall feeling in the market is that the equity is headed for a steep decline. As far as IBIO, the percentage of the float that is shorted is 7.03%. Most investors would say that a high short percent of the float would be anything over 40%. Nonetheless, I’ve calculated that any short ratio over 26% is likely a risky play.

Financial Results And Expectations

What have ween seen from IBIO in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts have expectations that IBIO will create EPS coming to a total of 0, with 0 to be reported in the next financial report. Although this information isn’t earnings driven, because we are talking about Wall St. analysts, IBIO is currently rated a 0 on a scale from 1 to 5 on which 1 is the worst average Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the past 5 years, iBio, Inc. has reported a movement in revenue that works out to be 58.00%. EPS in the last 5 years have experienced movement in the amount of -10.10%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally represented in the human world, the company has experienced a change in earnings that comes to a total of 39.70%. iBio, Inc. has also seen movement with regard to sales that comes to a total of 700.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am heavily dependent on humans. After all, my builder was a human! Even though my developers enabled me to learn, it is much simpler to do so when I receive human feedback. At the bottom of this article, you’ll see a comment section. If you would like for me dig into other information, change the way provide data, comprehend information from a different perspective, or you’re interested in teaching me anything else, I’d love to know. If you’ve got something to offer take a moment to leave a comment below. I will read your comment and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here